Genentech’s inhaled JAK1 inhibitor shows promise in asthma by Angus Liu Wednesday, November 21, 2018 Genentech's lung-restricted JAK1 inhibitor reduced lung inflammation and airway symptoms in rodent models of asthma.
Concert’s alopecia drug hits phase 2 endpoint with more data to come by Amirah Al Idrus Monday, November 12, 2018 Concert Pharmaceuticals’ alopecia drug reduced disease severity in nearly half of the patients who received a higher dose.
Gilead, Galapagos’ filgotinib aces first phase 3 by Nick Paul Taylor Wednesday, September 12, 2018 The data suggest filgotinib is safe and as effective as JAK rivals including AbbVie’s upadacitinib, setting the stage for a four-way commercial scrap.
Gilead, Galapagos’ filgotinib hits goals in phase 2 by Nick Paul Taylor Thursday, September 6, 2018 The results position the potential blockbuster to advance into phase 3 in ankylosing spondylitis, although a safety signal gave investors a scare.
With just $3M upfront, Sierra buys an unwanted Gilead drug by Ben Adams Wednesday, August 22, 2018 Gilead paid billions to get into the CAR-T game with its purchase of Kite Pharma, and now it's looking to offload some unwanted cancer assets.
Jefferies says Gilead JAK inhibitor could drive turnaround by Phil Taylor Thursday, July 5, 2018 Gilead is eagerly awaiting phase 3 data for its rheumatoid arthritis drug filgotinib that could be an antidote for the biotech’s hepatitis C hangover.
FDA ‘conflicted’ on Lilly and Incyte’s refiled baricitinib by Phil Taylor Friday, April 20, 2018 Eli Lilly and Incyte’s second attempt to get U.S. approval of rheumatoid arthritis drug baricitinib may be scuppered again by FDA concerns on safety.
Janssen, Theravance ink GI pact worth up to $1B by Amirah Al Idrus Wednesday, February 7, 2018 Theravance will bring its GI drug through phase 2/3 in Crohn's disease and ulcerative colitis.
J.P. Morgan kicks off with a deal as Celgene pays $1.1B for Impact by Ben Adams Monday, January 8, 2018 On the first day of the big biotech conference that is J.P. Morgan, Celgene has come right out on day one with M&A news.
Galapagos takes up filgotinib co-promotion option by Nick Paul Taylor Friday, December 15, 2017 Galapagos has taken up its option to co-promote filgotinib with Gilead in certain European nations, but Gilead will be free to acquire its partner in two weeks.
